Cláudia Vaz de Melo Sette

Faculdade de Medicina do ABC

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Auro del Giglio

Faculdade de Medicina do ABC

Daniel de Iracema Gomes Cubero

Faculdade de Medicina do ABC

Jean M. Hébert

Albert Einstein College of Medicine

Fernando Luiz Affonso Fonseca

Faculdade de Medicina do ABC

Karine Corcione Turke

Faculdade de Medicina do ABC

Igor Bondarenko

Dnipropetrovsk State Medical Academy

Camila Ribeiro de Arruda Monteiro

Faculdade de Medicina do ABC

Igor Luiz Argani

Faculdade de Medicina do ABC

Thiago Artioli

Faculdade de Medicina do ABC

Bárbara Bonaparte Ribas de Alcântara

Faculdade de Medicina do ABC

Cooperative Institutions

Faculdade de Medicina do ABC

Sarah Cannon

Tennessee Oncology

Istituti di Ricovero e Cura a Carattere Scientifico

Peking University

Inserm

National Cancer Center

Johns Hopkins University

Yonsei University

Instituto Brasileiro de Controle do Câncer

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

P2.31-09 Missed Opportunities for Lung Cancer Personalized Medicine in a Brazilian Public Healthcare Service

Journal of Thoracic Oncology (2023)

Luma Princess Schneider Pedro Nazareth Aguiar Marcos Aurélio Fonseca Magalhães Filho Jean M. Hébert Cláudia Vaz de Melo Sette

Personalized Medicine

Profiling (computer programming)

Healthcare system

Public healthcare

10.1016/j.jtho.2023.09.735

Cite

Citations (0)

Curcuma longa (Turmeric) for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Pilot Study

Journal of Dietary Supplements (2017)

Vanessa Armenio Scontre Janine Capobiango Martins Cláudia Vaz de Melo Sette Haila Mutti Daniel de Iracema Gomes Cubero

Hand-foot syndrome (HFS) is common and frequently occurs in the first cycle of treatment in approximately 40% to 50% of patients who receive capecitabine. Turmeric (Curcuma longa) is a plant used in Ayurvedic medicine with clinical activity in various inflammatory conditions. Our objective was to evaluate whether turmeric was active for the prevention of capecitabine-induced HFS. We included patients older than 18 years of age without previous exposure to capecitabine who were scheduled to receive this medication. Before starting treatment, after three weeks and at the end of six weeks, we evaluated dermatologic toxicity, conducted quality-of-life questionnaires (EORTC-QLQC30 and DLQI) and collected serum inflammatory biomarkers (inerleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), C-reactive protein (CRP), and albumin). We administered turmeric at a dose of 4 g/day (2 pills 12 hours apart) starting at the beginning of capecitabine treatment and lasting six weeks. We included 40 patients whose mean age was 62 years. Most were female (80%), 52% had breast cancer, and 47.5% had GI tumors. After the first cycle of capecitabine treatment, we observed that 11 of 40 patients developed HFS (27.5%; 95% CI [15, 42]), whereas four patients developed HFS equal or superior to grade 2 (10%; 95% CI [3.3, 23]). We did not find any correlations between the inflammatory markers tested and HFS. We show that turmeric combined with capecitabine seems to produce a lower rate of HFS, especially grade 2 or higher. These findings need to be reproduced in larger controlled studies.

Pill

10.1080/19390211.2017.1366387

Cite

Citations (19)

Editorial

Clinical Oncology Letters (2018)

Auro del Giglio Cláudia Vaz de Melo Sette

Caro leitor, Ã um imenso prazer lhe entregar o mais novo volume de nossa revista! O verdadeiro intuito da produÃ§Ã£o de artigos cientÃficos encontra-se na disseminaÃ§Ã£o de conhecimento, possibilitando sua aplicabilidade clÃnica. PorÃ©m, em muitos aspectos, a realidade brasileira mostra-se Ãmpar, principalmente no que diz respeito aos serviÃ§os ofertados pelo Sistema Ãnico de SaÃºde (SUS). Dessa forma, um dos principais intuitos de nossa revista Ã© promover a publicaÃ§Ã£o de artigos nacionais, idealizados e desenvolvidos em meio ao SUS, a fim de assegurar a divulgaÃ§Ã£o de resultados que melhor representem a realidade nacional. Nesta ediÃ§Ã£o, o leitor encontrarÃ¡ artigos versando sobre mudanÃ§a da expressÃ£o imunofenotÃpica em tumores mamÃ¡rios rebiopsiados apÃ³s algum tempo, a experiÃªncia do nosso serviÃ§o com o tratamento de Leucemia MielÃ³ide CrÃ´nica, uma revisÃ£o da eficÃ¡cia do guaranÃ¡ nos vÃ¡rios trabalhos conduzidos em nossa Faculdade, alÃ©m de outras interessantes contribuiÃ§Ãµes. Por fim, gostarÃamos de convidÃ¡-lo, tambÃ©m, a conhecer nosso site1, onde encontrarÃ¡ o conteÃºdo da revista disponibilizado na Ãntegra, assim com as normas para submissÃ£o e publicaÃ§Ã£o de artigos. Uma Ã³tima leitura!

10.4322/col.2018.010

Cite

Citations (0)

Ovarian cancer mortality: implications of income-inequality and availability of medical doctors in Brazil.

Journal of Clinical Oncology (2022)

Jean Henri Maselli-Schoueri Luis Eduardo Werneck De Carvalho Laércio da Silva Paiva Manuela de Almeida Roediger Luíz Carlos de Abreu

e22520 Background: Ovarian cancer mortality varies by region and age group in Brazil. However, it is still unknown if socioeconomic inequalities may affect its outcome even if indirectly as it happens for other gynecologic neoplasms in the country. Methods: Ecological study conducted with secondary data from 2016-2018 to examine the relationship between income-inequality and the amount of doctors per inhabitant on ovarian cancer mortality in Brazil. All data were gathered from Brazil’s public health system. Mortality was analyzed by sex and age, which was standardized according to the World Health Organization’s population. Income-Inequality was measured using the Gini index, obtained from the United Nations Development Programme. The number of doctors was obtained from the Unified Health System and was also calculated as the rate per 100,000 inhabitants. Linear regression was performed using stepwise selection/backward elimination. Results: Despite income inequality as measured by the Gini index not having any statistically significant relationship with ovarian cancer mortality rates, we found that the amount of doctors per inhabitant was positively associated with ovarian cancer mortality rates (β 0.037, IC95% 0.028;0.045), whereas the amount of clinical oncologists (β-0.426, IC95% -0.805; -0.047) and higher income (β -0.004, IC95% -0.005; -0.003) were all negatively associated with those rates (p < 0.05), meaning that the higher those variables, the lower the mortality. Conclusions: Ovarian cancer mortality differs among federative units in Brazil. Higher mortality is associated with a greater amount of doctors per inhabitant, whereas lower mortality rates were found to be associated with higher income and more clinical oncologists available.

Ecological study

Affect

10.1200/jco.2022.40.16_suppl.e22520

Cite

Citations (0)

Time trend and regional variability of mortality rate due to ovarian cancer in Brazil: a 15-year analysis

Journal of Public Health (2018)

Jean M. Hébert Fernando Alves Affonso Kaufman Celeste Rodovalho Soares de Camargo Cláudia Vaz de Melo Sette Fernando Adami

Ovarian cancer (OC) is the most lethal gynecological tumor. In Brazil, there are important regional differences regarding mortality rates for the same cancer type.To analyze the progression of OC mortality rates in Brazil and its regions, in age groups over 50 years, between 2000 and 2015.Ecological longitudinal study carried out using secondary data from DATASUS (Brazil's public health system database) regarding deaths due to OC in women living in Brazil between 2000 and 2015. We calculated gross and adjusted mortality, estimated the impact of death of OC and proportional mortality rate of all cancer types in women between the age of 50 and 79 years.There were 34.335 deaths due to OC in women in the referred age interval, with a 9% increase in mortality adjusted for age, a 0.05% (P = 0.012) trend and a 24.67% increase in the proportional mortality due to all causes with a 0.02% (P < 0.001) trend. There were statistically significant increases in mortality rates due to OC in the age groups of 50-54 (28,4%, P < 0,05) and 75-79 years (25,1%, P < 0,05).Although there are oscillations in mortality rates of OC in Brazil and its regions over the period studied, this parameter has remained relatively stable.

10.1093/pubmed/fdy080

Cite

Citations (3)

Malignant pericardial effusion as a primary manifestation of metastatic colon cancer: a case report

Journal of Medical Case Reports (2021)

Milena Brachmans Mascarenhas Neves Mirella Velasco Stival Yuri Costa Sarno Neves Jordânia Gonçalves Pereira da Silva Daniela Borges da Rocha Macedo

Abstract Background Pericardial neoplastic involvement is rarely related to primary tumors of the pericardium and is most often caused by spread from other primary sites, such as lung and breast carcinomas, hematological malignancies (lymphoma and leukemia), and melanoma. Although pericardial metastasis from infradiaphragmatic tumors (such as colon cancers) are rare and poorly described in literature, any neoplasm has the potential to metastasize to the pericardium and heart by either contiguity, lymphatic, or hematological spread. Case presentation A 44-year-old previously healthy male Causasian patient had a sudden onset of dyspnea and wheezing. During investigation with echocardiogram, computed tomography and repeated pericardiocentesis, the cause of malignant pericardial effusion was confirmed as primary manifestation of metastatic colon cancer. The patient was treated with appropriate chemotherapy and presented satisfactory disease control. Conclusions This report emphasizes the importance of considering the diagnostic hypothesis of occult neoplasia in a patient with pericardial effusion.

Pericardiocentesis

Surgical oncology

Occult

10.1186/s13256-021-03085-w

Cite

Citations (6)

Novel approach for cancer-related fatigue: A double-blind randomized clinical trial.

Journal of Clinical Oncology (2017)

Cláudia Vaz de Melo Sette Bárbara Bonaparte Ribas de Alcântara Felipe Melo Cruz Jean M. Hébert Daniel de Iracema Gomes Cubero

234 Background: Fatigue is one side effect of cancer and its treatment, and remains as the most prevalent symptom for those who survived. To date, the search for novel approaches regarding Cancer-Related Fatigue persists. As such, Paullinia cupana – a medicinal plant – has shown promising results for the treatment of chemotherapy-induced fatigue. Methods: We conducted a phase II randomized double-blind clinical trial, in which we compared a standardized dry purified Paullinia cupana extract (PC-18) - in doses of 7.5 mg and 12.5 mg given orally twice a day - to placebo for the treatment of fatigue in women with early breast cancer scheduled to receive their first cycle of adjuvant systemic chemotherapy. Only patients that experienced increase in the score of either BFI, HAD or Chalder fatigue scales following the first cycle of chemotherapy were included. For possible associations between qualitative variables, Chi-square test was used. Poisson regression was used to test for the relationship between the drug used and the outcome regarding the difference assessed in scores aforementioned. The significance level was 5%. The program used was Stata 12.0. This study has been approved by our Institutional Review Board (number: 34327214.1.1001.0082) and participants have all signed informed consent forms. Results: PC-18 on 7.5 mg has not been statistically significant with any improvements on assessed scores when compared to placebo (IRR 0.99 [CI] 0.81 – 1.23, p = 0.958 for BFI; IRR 1.04 [CI] 0.56 – 1.95, p = 0,898 for HAD; IRR 0.95 [CI] 0.75 – 1.19, p = 0.645 for Chalder), while greater dosage (12.5mg) has shown the following outcomes regarding the scores (IRR 0.49 [CI] 0.30 – 0.81, p = 0.005 for BFI; IRR 0.89 [CI] 0.45 – 1.76, p = 0,735 for HAD; IRR 0.99 [CI] 0.80 – 1.23, p = 0.914 for Chalder) in the same comparison. Conclusions: Disregarding preliminary data on previous studies, PC-18 has not shown to be better than placebo. Clinical trial information: 34327214.1.1001.0082.

Cancer-related fatigue

10.1200/jco.2017.35.31_suppl.234

Cite

Citations (0)

Perfil Epidemiológico e Análise de Sobrevida em Pacientes com Neoplasia de Pulmão tratados em um Hospital Público no Município de São Bernardo do Campo - SP: um Estudo Retrospectivo

Clinical Oncology Letters (2020)

Stéphane Tomás da Luz Patrícia Xavier Santi Daniel de Iracema Gomes Cubero Jean M. Hébert Auro del Giglio

IntroduÃ§Ã£o: O cÃ¢ncer de pulmÃ£o (CP) Ã© uma das neoplasias mais comuns de todos os tumores malignos, com letalidade e incidÃªncia crescente principalmente entre mulheres. Objetivos: Avaliar fatores epidemiolÃ³gicos e sobrevida de pacientes com CP de um hospital pÃºblico de SÃ£o Bernardo do Campo-SP-Brasil e correlacionÃ¡-los com dados apresentados em estudos na Ã¡rea. MÃ©todo: Estudo retrospectivo a partir da anÃ¡lise dos prontuÃ¡rios de pacientes diagnosticados com CP (CID 10: C34), acompanhados no Hospital Anchieta de SÃ£o Bernardo do Campo - SP, no perÃodo de 01/06/2016 a 01/07/18. Para anÃ¡lise de sobrevida, utilizou-se as curvas de Kaplan-Meier com teste de log rank. O software utilizado foi o StataÂ® versÃ£o 11.0 Resultados: Dos 80 pacientes incluÃdos, a mÃ©dia de idade foi de 68 anos entre homens e 64 entre mulheres, sendo 41% do tipo histolÃ³gico adenocarcinoma e 34% de CEC. Cerca de 76% eram avanÃ§adas ao diagnÃ³stico e quase 41% com ECOG 1 ao diagnÃ³stico. Quanto Ã quimioterapia, 35% receberam primeira linha baseada em platina no adenocarcinoma, 53% no CEC e 56% no pequenas cÃ©lulas. Na amostra estudada, 56% evoluÃram a Ã³bito, sendo que 18% apÃ³s o diagnÃ³stico, sem ter recebido qualquer linha de tratamento. A mediana de sobrevida global foi 11 meses. ConclusÃ£o: Os pacientes atendidos neste hospital pertencente ao sistema pÃºblico brasileiro apresentaram sobrevida muito pequena, divergindo dos resultados encontrados na literatura, provavelmente devido Ã dificuldade de acesso ao sistema de saÃºde especializado e do estÃ¡gio avanÃ§ado do diagnÃ³stico.

10.4322/col.2019.004

Cite

Citations (0)

Avaliação da Cardiotoxicidade induzida por Quimioterapia em pacientes com Câncer de Mama

Clinical Oncology Letters (2018)

Igor Luiz Argani Camila Ribeiro de Arruda Monteiro Jean M. Hébert Mirella Regina Cimino Scaff F Kaufman

Objetivo: Avaliar a alteraÃ§Ã£o da funÃ§Ã£o cardÃaca em pacientes com cÃ¢ncer de mama tratadas com quimioterapia. MÃ©todos: Estudo observacional retrospectivo com coleta de dados em prontuÃ¡rio no Hospital MÃ¡rio Covas (Santo AndrÃ© â Brasil). Avaliou-se a fraÃ§Ã£o de ejeÃ§Ã£o obtida pelo ecocardiograma (ECO) antes do tratamento quimioterÃ¡pico, em comparaÃ§Ã£o com o ECO ao final do tratamento. Resultados: Foram incluÃdas 234 pacientes com cÃ¢ncer de mama submetidas a QT, das quais 100 realizaram ao menos um ECO e 33, pelo menos dois exames. Desse total, apenas 18 puderam ser analisados, pois apresentavam ECO feito corretamente, i.e., antes e depois do tratamento quimioterÃ¡pico. Analisando esses ECOs, observou-se diferenÃ§a da fraÃ§Ã£o de ejeÃ§Ã£o mÃ©dia de 5% (IC95% 2,9-7,6; p=0,0001). ConclusÃ£o: A alta prevalÃªncia e o expressivo aumento da sobrevida de pacientes com cÃ¢ncer de mama indicam a necessidade de acompanhamento adequado dos efeitos a longo prazo da QT. A anÃ¡lise dos ECO feitos adequadamente nos pacientes com cÃ¢ncer de mama nesse estudo demonstrou significante queda da fraÃ§Ã£o de ejeÃ§Ã£o, confirmando os efeitos cardiotÃ³xicos da QT. Apesar disso, apenas uma fraÃ§Ã£o pouco expressiva dos pacientes apresentou acompanhamento adequado.

10.4322/col.2018.002

Cite

Citations (2)

Induction Therapy With Cisplatin, 5-Fluorouracil, Leucovorin, and Paclitaxel in Patients With Head and Neck Cancer

In Vivo (2023)

CARLOS EDUARDO COELHO DE DANIEL DE IRACEMA GOMES CUBERO RAFAEL EVERTON ASSUNCAO RIBEIRO DA COSTA RENATO DI PARDO FELIPE JOSE SILVA MELO CRUZ

Background/Aim: This study aimed to evaluate the toxicities and response rate of a modified TPF (docetaxel, cisplatin, and 5-fluorouracil) protocol in patients with locally advanced head and neck cancer (ECOG performance status ≤1). Patients and Methods: Induction treatment consisted of cisplatin 25 mg/m²/day as a 90 min infusion for three consecutive days, leucovorin 20 mg/m²/day as a bolus for four consecutive days, 5-fluorouracil (5-FU) 370 mg/m²/day as a bolus for four consecutive days, and paclitaxel 60 mg/m² as a 1-h infusion on Days 1, 8, and 15, repeated every 3-4 weeks (twelve cycles to 6 patients). Results: The main toxicities were grade 1 neuropathy, mucositis, and fatigue. There were four episodes of severe toxicities (grade ≥3). There was one early death, and 2 patients were discontinued due to hematological toxicity. Other side effects included neutropenia, nausea, diarrhea, and vomiting. Conclusion: Induction therapy with cisplatin, 5-fluorouracil, leucovorin, and paclitaxel in head and neck cancer is not feasible because of severe toxicity.

Mucositis

Bolus (digestion)

10.21873/invivo.13215

Cite

Citations (0)